Mitchell Lab: Lipid nanoparticles that deliver mRNA to T cells show potential treatment for autoimmune diseases
The goal of this platform is to engineer adoptive cell therapies inside of the body for specific autoimmune diseases.
Cabaletta Bio Receives Another FDA Clearance for IND application of CABA-201
The company plans to initiate a Phase 1/2 clinical trial of CABA-201 in two cohorts of patients with generalized myasthenia gravis (gMG).
Heirloom Opens First Commercial Carbon Capture Plant in the U.S.
Heirloom uses a process called direct air capture to remove greenhouse gases from the atmosphere.
First canine patient receives Vetigenics’ fully canine anti-CTLA4 monoclonal antibody
Vetigenics announced that the first canine patient has received his first dose of Vetigenics' fully canine anti-CTLA4 monoclonal antibody (VGS-001) for oral melanoma.
Cabaletta Bio Receives FDA Clearance of CABA-201 Investigational New Drug Application for Treatment of Generalized Myasthenia Gravis
Cabaletta Bio received FDA clearance for their fourth Investigational New Drug application of CABA-201, their CAR T cell investigational therapy, to treat patients with generalized myasthenia gravis.
Philadelphia region designated a federal tech hub for life sciences
The Philadelphia region has been designated as a federal innovation and technology hub, allowing it to compete for a grant of up to $75 million to advance its life sciences industry.
Emily Whitehead, the first child to be cured of cancer with Penn-invented CAR-T therapy, is now a freshman at Penn
From American Sign Language to English to nature photography, Emily has a wide range of interests she intends to explore in her studies.
Penn spinout Interius Biotherapeutics raises another $21.5M
Co-founded by Saar Gill, MD, PhD, Interius is developing a new platform for cell-specific gene delivery in patients.
Penn Faculty Discover An Innovative Potential Treatment for Tooth Decay
In search of a more effective treatment, the research team employed a combination of ferumoxytol (Fer) and stannous fluoride (SnF2) to fight tooth decay.
FloBio Receives the FDA’s Breakthrough Device Designation for its Bleeding Risk Diagnostic Test
FloBio's test determines blood clotting status and identifies whether a patient is on popular blood thinners called Direct Oral Anticoagulants (DOACs).